Company
Headquarters: Taipei City, Taiwan
Employees: 35
TW$14.66 Billion
TWD as of July 1, 2024
US$450.3 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04 for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V07 glycan-based vaccines and drugs. The company was founded in 2013 and is based in Taipei City, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
CHO Pharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 6586 wb_incandescent